Sun Xiaoqing, Cao Jianghua, Sun Peng, Yang Hang, Li Huan, Ma Wenjuan, Wu Xianqiu, He Xiaohua, Li Jing, Li Zhiming, Huang Jiajia
Department of Intensive Care Unit(ICU), State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
Department of Medical Oncology, State Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, 510060, PR China.
Biomark Med. 2023 Feb;17(3):143-158. doi: 10.2217/bmm-2022-0764. Epub 2023 Apr 25.
To explore the clinical association between soluble Siglec-5/CD163 and clinical feature and prognosis in peripheral blood samples of patients with diffuse large B-cell lymphoma. Significantly elevated cytokines in peripheral blood were characterized by cytokines array and validated by ELISA. Compared with CD163, Siglec-5 exhibited superiority in discriminating patients into low- and high-risk subgroups based on overall survival and progression-free survival. In addition, Siglec-5 was an indicator of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) treatment efficacy. Siglec-5 may be applied as a reliable independent immune indicator for overall survival and progression-free survival. It may also predict R-CHOP efficacy in diffuse large B-cell lymphoma.
探讨弥漫性大B细胞淋巴瘤患者外周血样本中可溶性唾液酸结合免疫球蛋白样凝集素-5（Siglec-5）/CD163与临床特征及预后之间的临床关联。通过细胞因子阵列对外周血中显著升高的细胞因子进行表征，并通过酶联免疫吸附测定（ELISA）进行验证。与CD163相比，基于总生存期和无进展生存期，Siglec-5在将患者分为低风险和高风险亚组方面表现出优势。此外，Siglec-5是利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松（R-CHOP）治疗疗效的一个指标。Siglec-5可作为总生存期和无进展生存期的可靠独立免疫指标应用。它还可能预测弥漫性大B细胞淋巴瘤的R-CHOP疗效。
